NIMH Chemical Synthesis & Drug Supply Program

NIMH化学合成和药物供应计划的目的是合成、纯化和提供商业来源无法获得的必需化合物（例如，库存已经耗尽，将不再补充，在进行临床试验时无法获得的专利化合物等）促进与精神健康相关的基础和临床研究，如CNS受体的分子药理学和信号传导，评估精神活性化合物的分子，生物化学和行为作用的纵向研究，以及灵长类动物和人类的功能性脑成像。目前的倡议集中在目前的GMP（良好的生产规范）和非GMP化合物的基础和临床研究，如新的中枢神经系统受体亚型选择性激动剂和拮抗剂，放射性标记的化合物，和新的PET，SPECT和功能性脑成像功能磁共振成像配体的合成。

The purpose of the NIMH Chemical Synthesis and Drug Supply Program is to synthesize, purify, and provide essential compounds that are unavailable from commercial sources (e.g., the stock has been depleted and it will not be replenished, patented compounds that are unavailable while undergoing clinical trials, etc.) to stimulate basic and clinical research relevant to mental health in areas such as the molecular pharmacology and signaling of CNS receptors, longitudinal studies to evaluate the molecular, biochemical, and behavioral actions of psychoactive compounds, and functional brain imaging in primates and humans. The present initiative focuses on the synthesis of current GMP (Good Manufacturing Practices) and non-GMP compounds for basic and clinical research such as novel central nervous system receptor subtype-selective agonists and antagonists, radiolabeled compounds, and novel PET, SPECT, and fMRI ligands for functional brain imaging.